Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
July 6, 2022
We are very excited to announce that we have closed the two newest funds of the TCG fund family – The Column Group V (“TCG V”), a $615 million fund focused on early-stage investments, and The Column Group Opportunity III (“TCG Opportunity III”), also $615 million but focused on later stage investments in our companies.
The Column Group Raises $1.23 Billion in Two New Funds Read More »